REVEAL III: Risk Evaluation and Education for Alzheimer's Disease

Summary

The purpose of this study is to provide healthy adults with genetic testing and information about their chances of developing Alzheimer's disease.

Conditions

• Alzheimer Disease

Interventions

BEHAVIORAL

Pleiotropic info, in-person disclosure

Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information. Genetic counselors communicate results to participants during an in-person disclosure session.

BEHAVIORAL

AD-only info, in-person disclosure

Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping. Genetic counselors communicate results to participants during an in-person disclosure session.

BEHAVIORAL

Pleiotropic info, phone disclosure

Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information. Genetic counselors communicate results to participants during a telephone disclosure session.

BEHAVIORAL

AD-only info, phone disclosure

Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping. Genetic counselors communicate results to participants during an in-person disclosure session.

Sponsors & Collaborators

• National Human Genome Research Institute (NHGRI)

  collaborator NIH

• Brigham and Women's Hospital

  lead OTHER

Principal Investigators

• Robert Green, MD, MPH · Brigham and Women's Hospital

Study Design

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE

Model

FACTORIAL

Eligibility

Min Age

18 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2007-03-31

Primary Completion

2009-10-31

Completion

2009-10-31

Countries

• United States

Study Locations